Table 3: Frequency of metabolic and cardiovascular comorbidities observed by type of ARV and duration of treatment.

Comorbidities	Total	NNRTI-based	PI-based/ rescue	p value	< 5 years	≥ 5 years	p value
		(n=233)	(n=72)		(n=89)	(n=216)
Dyslipidemia, n (%)	157 (51.5)	122 (52.4)	35 (48.6)	0.336	39 (43.8)	118 (54.6)	0.005
Obesity, n (%)	34 (11.1)	24 (10.3)	10 (13.9)	0.258	12 (13.5)	22 (10.2)	0.259
Excess weight, n (%)	127 (41.6)	102 (43.8)	25 (34.7)	0.109	36 (40.5)	91 (42.1)	0.444
Diabetes mellitus, n (%)	22 (7.2)	19 (8.2)	3 (4.2)	0.191	3 (3.4)	19 (8.8)	0.071
Hypertension, n (%)	27 (8.9)	23 (9.9)	4 (5.6)	0.188	4 (4.5)	23 (10.6)	0.061
Cardiovascular diseases, n (%)	10 (3.3)	6 (2.6)	4 (5.6)	0.189	1 (1.1)	9 (4.2)	0.158
Impairment of renal function, n (%)	19 (6.2)	12 (5.1)	7 (9.7)	0.131	4 (4.5)	15 (6.9)	0.301